根据美国证券交易委员会（SEC）最新披露的文件，生物制药公司Terns Pharmaceuticals与默沙东（Merck）的合作协议中包含特殊条款：若交易因特定情况被迫终止，Terns Pharmaceuticals将需向默沙东支付高达2.35亿美元的终止费用。
这一条款凸显了双方对合作关系的严肃承诺，同时也反映出生物医药领域大型交易中常见的风险对冲机制。巨额解约金的设定，既保障了默沙东在合作可能中断时的利益，也体现了Terns Pharmaceuticals对项目前景的坚定信心。
根据美国证券交易委员会（SEC）最新披露的文件，生物制药公司Terns Pharmaceuticals与默沙东（Merck）的合作协议中包含特殊条款：若交易因特定情况被迫终止，Terns Pharmaceuticals将需向默沙东支付高达2.35亿美元的终止费用。
这一条款凸显了双方对合作关系的严肃承诺，同时也反映出生物医药领域大型交易中常见的风险对冲机制。巨额解约金的设定，既保障了默沙东在合作可能中断时的利益，也体现了Terns Pharmaceuticals对项目前景的坚定信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.